Hormonal
Low serum testosterone levels (defined as <8.7 nmol/L or <250 ng/dL) are associated with a significantly increased risk of all-cause, cardiovascular, and cancer mortality in men aged 20-79, independent of age, waist circumference, smoking, alcohol use, physical activity, and renal function.
For men aged 20-79, having serum testosterone below 8.7 nmol/L (250 ng/dL) is a significant predictor of higher all-cause, cardiovascular, and cancer mortality risk, independent of lifestyle factors like smoking or exercise. This association holds even after adjusting for age, waist circumference, and kidney function. While testosterone itself may not be the direct cause of death, it serves as a critical biomarker for underlying health risks, particularly in older men (60-79 years).
Men with low serum testosterone levels had a significantly higher mortality from all causes than men with higher serum testosterone levels (HR 2.24; 95% CI 1.41–3.57)... low serum testosterone levels continued to be associated with increased mortality (HR 2.32; 95% CI 1.38–3.89)... low serum testosterone levels predicted increased risk of death from cardiovascular disease (CVD) (HR 2.56; 95% CI 1.15–6.52) and cancer (HR 3.46; 95% CI 1.68–6.68)
Why this rating
Large population-based prospective cohort (n=1954) with long follow-up (7.2 years) and rigorous adjustment for confounders, though observational design limits causal inference.
Source
Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79
Robin Haring et al. · European Heart Journal · 2010
DOI 10.1093/eurheartj/ehq009
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →